Dementia and Alzheimer Disease

Ahead of the 2026 Alzheimer's Association International Conference, David Wolk, MD, discusses the meeting's biggest scientific themes, from plasma biomarkers and disease-modifying therapies to emerging technologies and evolving clinical practice.

Led by Na Tosha Gatson, MD, PhD, FAAN, director of the Center for Neuro-Oncology at the Indiana University Health Neurosciences and Cancer Institutes, this new column translates complex neuro-oncology topics into accessible, evidence-based insights.

Cleveland Clinic pilots HAP-E, guiding older adults to manage epilepsy and cognitive decline with lifestyle tools, medication support, and virtual access.

Optometrist DeAnn Fitzgerald, OD, discussed strategies to identify vision-related symptoms of TBI, the role of detailed history-taking, and the cultural considerations when caring for Hispanic patients.

Catch up on any of the neurology headlines you may have missed in June 2026, compiled into 1 place by the NeurologyLive® team.

Additional analyses from a phase 2 study evaluating the effects of zervimesine on hallucination in DLB will be presented at the Alzheimer's Association International Conference 2026 .

In the exploratory phase 2 RoAD study, PrimeC demonstrated biomarker changes consistent with target engagement across multiple neurodegenerative pathways, informing the design of future Alzheimer's disease trials.

Ashish Raj, PhD, professor of radiology and biomedical imaging at UCSF, discusses a newly developed AI model that predicts current and future cognitive impairment from a single baseline MRI scan in patients across the Alzheimer disease spectrum.

The 2026 Alzheimer disease drug development landscape highlights a growing shift toward diverse disease-modifying strategies, from amyloid and tau targeting to metabolic and neuroprotective approaches.

The associate professor of neurology and neuroscience at the Icahn School of Medicine at Mount Sinai discussed plasma p-tau217 levels association with regional hypometabolism, cortical atrophy, and cognitive impairment in early symptomatic Alzheimer disease.

Maya Hrachova, DO, neurologist and neuro-oncologist at Allina Health Brain and Spine Institute, discusses the evolving role of neurologic consultation in cancer care and the importance of accurate diagnosis in complex oncology patients.

Catch up on any of the neurology headlines you may have missed in May 2026, compiled into 1 place by the NeurologyLive® team.

At ATMRD 2026, the professor of neurology at Georgetown University Medical Center discussed how clinicians can distinguish Alzheimer disease from Lewy body dementia. [WATCH TIME: 5 minutes]

Characterization of early-start TRAILBLAZER-ALZ 2 participants who required continued donanemab in the long-term extension suggests durable clinical benefit with fewer cumulative doses.

Preliminary phase 1a findings suggest the investigational tau aggregation inhibitor OLX-07010 demonstrated favorable safety and pharmacokinetic profiles in healthy volunteers, supporting continued development in Alzheimer disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 15, 2026.

The professor of cognitive neuroscience and imaging at the University of Western Ontario, Canada, detailed new research using the Creyos platform and machine learning to develop a rapid, scalable cognitive screener designed to identify early signs of cognitive decline and dementia risk.

Data from the phase 2 CELIA study of diranersen will be presented at the 2026 Alzheimer’s Association International Conference (AAIC) 2026, held July 12-15, in London, United Kingdom.

Experts shared their clinical perspectives and insights on main focus areas at the 2026 American Academy of Neurology (AAN) Annual Meeting, held April 18-22 in Chicago, Illinois.

H. E. Hinson, MD, MCR, FAAN, discussed how neurology is rapidly evolving toward interventional therapies, prevention-focused care, and adaptive trial designs, based on presentations from AAN 2026.

Kristine Yaffe, MD, distinguished professor at UCSF and SEQUINS Hall of Fame honoree, discusses dementia prevention, modifiable risk factors, and ongoing disparities in brain health and cognitive aging.

Gus Alva, MD, DFAPA, medical director of ATP Clinical Research, commented on the potential clinical impact of AXS-05 for agitation in Alzheimer disease, caregiver burden, and the evolving collaboration between neurology and psychiatry.

As a 2026 SEQUINS Hall of Fame honoree, James Galvin, MD, MPH, reflected on advancing equitable dementia care, culturally relevant cognitive assessment, and improving brain health outcomes across diverse communities.

As a 2026 SEQUINS Hall of Fame honoree, George Howard, DrPH, commented on decades of stroke disparities research, the impact of the REGARDS study, and why future efforts must focus more directly on upstream risk factors.

Kinan Muhammed, MD, PhD, consultant neurologist and co-founder and Chief Medical Officer for Kneu Health, discussed how smartphone-based remote monitoring tools may help clinicians track motor and cognitive changes in Parkinson disease and dementia more continuously.